VOR and 688331.SS Related Headlines
Go Back- VOR Bio's partner achieves primary endpoint in phase 3 Sjogren's disease trial
- Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
